JP2008520591A5 - - Google Patents

Download PDF

Info

Publication number
JP2008520591A5
JP2008520591A5 JP2007541607A JP2007541607A JP2008520591A5 JP 2008520591 A5 JP2008520591 A5 JP 2008520591A5 JP 2007541607 A JP2007541607 A JP 2007541607A JP 2007541607 A JP2007541607 A JP 2007541607A JP 2008520591 A5 JP2008520591 A5 JP 2008520591A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
clusterin
oligonucleotide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007541607A
Other languages
English (en)
Japanese (ja)
Other versions
JP4980919B2 (ja
JP2008520591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/001775 external-priority patent/WO2006056054A1/en
Publication of JP2008520591A publication Critical patent/JP2008520591A/ja
Publication of JP2008520591A5 publication Critical patent/JP2008520591A5/ja
Application granted granted Critical
Publication of JP4980919B2 publication Critical patent/JP4980919B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007541607A 2004-11-23 2005-11-22 Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療 Expired - Fee Related JP4980919B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52294804P 2004-11-23 2004-11-23
US60/522,948 2004-11-23
US52296004P 2004-11-24 2004-11-24
US60/522,960 2004-11-24
PCT/CA2005/001775 WO2006056054A1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels

Publications (3)

Publication Number Publication Date
JP2008520591A JP2008520591A (ja) 2008-06-19
JP2008520591A5 true JP2008520591A5 (cg-RX-API-DMAC10.html) 2008-11-27
JP4980919B2 JP4980919B2 (ja) 2012-07-18

Family

ID=36497699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007541607A Expired - Fee Related JP4980919B2 (ja) 2004-11-23 2005-11-22 Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療

Country Status (11)

Country Link
US (2) US20080014198A1 (cg-RX-API-DMAC10.html)
EP (1) EP1814595B1 (cg-RX-API-DMAC10.html)
JP (1) JP4980919B2 (cg-RX-API-DMAC10.html)
AU (1) AU2005309274B2 (cg-RX-API-DMAC10.html)
CA (1) CA2584646C (cg-RX-API-DMAC10.html)
DK (1) DK1814595T3 (cg-RX-API-DMAC10.html)
ES (1) ES2456017T3 (cg-RX-API-DMAC10.html)
PL (1) PL1814595T3 (cg-RX-API-DMAC10.html)
PT (1) PT1814595E (cg-RX-API-DMAC10.html)
SI (1) SI1814595T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006056054A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
RU2013145869A (ru) 2011-03-15 2015-04-20 Дзе Юниверсити Оф Бритиш Коламбиа КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
MD20140101A2 (ro) * 2013-02-22 2015-02-28 Alethia Biotherapeutics Inc. Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995017507A1 (en) * 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DK0882061T3 (da) * 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
NZ513757A (en) * 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2003062421A1 (en) * 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
AU2003237790A1 (en) * 2002-05-14 2003-12-02 Baylor College Of Medicine Small molecule inhibitors of her2 expression
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
CA2520518A1 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina

Similar Documents

Publication Publication Date Title
KR102443358B1 (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
ES2709495T3 (es) Modulación de la expresión del transductor de señales y activador de la transcripción 3 (stat3)
JP2023093644A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
EA015570B1 (ru) Фармацевтическая композиция
WO2015011694A2 (en) Isotopologues of smad7 antisense oligonucleotides
EA029137B1 (ru) Модулирование экспрессии вируса гепатита в (hbv)
EA009670B1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
CN104755621A (zh) 癌症治疗
CN113544271B (zh) Malat1表达的调节剂
JP2005530486A5 (cg-RX-API-DMAC10.html)
JP2016523548A (ja) 成長ホルモン受容体のモジュレータ
JP2006502243A5 (cg-RX-API-DMAC10.html)
JP2015503608A (ja) ベータ−カテニン関連疾患を処置するための有機組成物
JP7275164B2 (ja) Ｅｚｈ２発現の調節因子
JP6722586B2 (ja) アンチセンス抗悪性腫瘍剤
TW201016222A (en) RNA antagonists targeting GLI2
JP4980919B2 (ja) Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療
KR20150086442A (ko) ANT2 siRNA를 함유하는 HER2 표적 항암제에 대한 내성 극복을 위한 조성물
WO2021157730A1 (ja) 核酸医薬とその使用
JP7216381B2 (ja) Ｒｎａ作用抑制剤及びその利用
TW201102073A (en) RNA antagonists targeting GLI2 for the treatment of leukemia
HK40077247A (en) Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumours
RU2021102269A (ru) Олигонуклеотиды для модуляции экспрессии rtel1
HK40069167A (en) Compounds and methods for modulating angiotensinogen expression
Shahidullah Development of antisense radiopharmaceuticals for probing the molecular response of breast cancer cells to Trastuzumab